Sanofi shakes up clin­i­cal plans for trio of pro­grams from De­nali, Prin­cip­ia and Kymab deals

Sanofi is shuf­fling its pipeline af­ter sev­er­al tri­al flops in an­ti-in­flam­ma­to­ry and can­cer drugs it land­ed through a part­ner­ship with De­nali and buy­outs of Prin­cip­ia …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER